Grace (GRAC) Reports $7M FY26 Loss, Plans GTx-104 NDA Resubmission

Grace (GRAC) reported a net loss of $7 million for fiscal year 2026 and announced plans to resubmit its New Drug Application (NDA) for GTx-104, a treatment for subarachnoid hemorrhages. The company's financial results were released on June 22, 2026. The $7 million loss for FY26 was primarily attributed to increased research and development expenses associated with GTx-104's ongoing development and regulatory processes. Grace anticipates the resubmission of the GTx-104 NDA to the U.S. Food and Drug Administration (FDA) later in 2026, following additional data analysis and manufacturing adjustments requested by the agency.